minocycline

(redirected from Solodyn)
Also found in: Dictionary, Thesaurus.

minocycline

 [mĭ-no-si´klēn]
a semisynthetic broad-spectrum antibiotic of the tetracycline group; administered orally or intravenously as the hydrochloride salt

minocycline

/mi·no·cy·cline/ (mĭ-no-si´klēn) a semisynthetic broad-spectrum tetracycline antibiotic, used as the hydrochloride salt.

minocycline

(mĭn′ə-sī′klēn′, -klĭn)
n.
A broad-spectrum antibiotic, C23H27N3O7, derived from tetracycline and used usually in the form of its hydrochloride.

minocycline

A broad-spectrum tetracycline which has a longer serum half-life and achieves higher serum levels than simple tetracycline.

Indications
Acne, Lyme disease, MRSA, and other resistant microbes; it is also a recognised disease-modifying anti-rheumatic drug (DMARD).

Adverse effects
Vertigo, diarrhoea, patchy skin pigmentation, autoimmune disease.

minocycline

A TETRACYCLINE antibiotic used to treat ACNE and general infections. Brand names are Aknemin and Minocin.

minocycline

a second-generation, highly lipid-soluble derivative of tetracycline.
References in periodicals archive ?
Launched to dermatologists in July 2006 after approval by FDA on May 8, 2006, SOLODYN is the only branded oral minocycline approved for once daily dosage in the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
The dosing and administration for SOLODYN is based on extensive, multi-year clinical trials conducted by Medicis in which over 1,000 patients participated.
With the addition of the strengths announced in this press release, SOLODYN is now available by prescription in the eight following extended release tablet dosages:
When used as directed, SOLODYN is well tolerated and effective for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older.
The company expects product supply to be available for shipping to wholesalers within the quarter, and anticipates promotion and sample distribution of SOLODYN to physicians shortly after initial shipment.
The company currently has the US Food and Drug Administration's approval for eight dosing strengths of Solodyn - 45 mg, 55 mg, 65 mg, 80 mg, 90 mg, 105 mg, 115 mg and 135 mg - offering greater prescribing flexibility to physicians.
Solodyn comes in 45-mg, 90-mg, and 135-mg extended-release tablets.
Headache, fatigue, and dizziness were the most common adverse events in Solodyn clinical trials.
Researchers compared a total of 615 patients treated with Solodyn to 309 treated with placebo.
In one study, 17% of Solodyn patients were clear or almost clear, compared with 8% of placebo patients; the second study demonstrated a similar 16% versus 10% result.
Keri has no financial relationship with Solodyn or Medicis.